PYXS

1.11

6.72% -0.08

Dopo l'orario di chiusura: 1.11

Pyxis Oncology Inc (PYXS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PYXS Giù? Forum Previsione

Precedente Chiudi:

$1.19

Aprire:

$1.21

Volume 24 ore:

495.97K

Relative Volume:

0.51

Capitalizzazione di mercato:

$71.66M

Reddito:

Utile/perdita netta:

$-73.79M

Rapporto P/E:

-0.6033

EPS:

-1.84

Flusso di cassa netto:

$-77.44M

1 W Prestazione:

-9.02%

1M Prestazione:

-26.00%

6M Prestazione:

-67.73%

1 anno Prestazione:

-83.16%

Intervallo 1D:

$1.105

$1.22

Intervallo di 1 settimana:

$1.105

$1.325

Portata 52W:

$1.105

$6.79

Pyxis Oncology Inc Stock (PYXS) Company Profile

Nome

Pyxis Oncology Inc

Settore

Healthcare (1189)

Industria

Biotechnology (682)

Telefono

(617) 221-9059

Indirizzo

321 HARRISON AVENUE, BOSTON

Dipendente

Cinguettio

Prossima data di guadagno

2024-08-11

Ultimi documenti SEC

PYXS's Discussions on Twitter

Confronta PYXS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PYXS Pyxis Oncology Inc	1.11	71.66M	0	-73.79M	-77.44M	-1.84
VRTX Vertex Pharmaceuticals Inc	483.31	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	27.34B	3.30B	-501.07M	1.03B	-2.1146

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-21	Downgrade	William Blair	Outperform → Mkt Perform
2024-11-08	Iniziato	Stephens	Overweight
2024-08-08	Iniziato	Stifel	Buy
2024-05-07	Ripresa	Jefferies	Buy
2024-02-09	Iniziato	BTIG Research	Buy
2024-01-23	Iniziato	Leerink Partners	Outperform
2023-09-05	Iniziato	RBC Capital Mkts	Outperform
2021-11-02	Iniziato	BofA Securities	Neutral
2021-11-02	Iniziato	Credit Suisse	Outperform
2021-11-02	Iniziato	Jefferies	Buy

Mostra tutto

Pyxis Oncology Inc Borsa (PYXS) Ultime notizie

07:46 AM

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times

07:46 AM

07:30 AM

Can Pyxis Oncology's CEO Reveal New Cancer Treatment Progress at Upcoming Leerink Conference? - StockTitan

07:30 AM

Feb 26, 2025

Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Marketscreener.com

Feb 26, 2025

FDA fast tracks Pyxis Oncology's head and neck cancer drug By Investing.com - Investing.com Canada

Feb 26, 2025

Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer - Nasdaq

Feb 26, 2025

PYXSPyxis Oncology, Inc. Latest Stock News & Market Updates - StockTitan

Feb 26, 2025

FDA fast tracks Pyxis Oncology’s head and neck cancer drug - Investing.com India

Feb 26, 2025

Pyxis Oncology stock up on FDA fast track tag (PYXS:NASDAQ) - Seeking Alpha

Feb 26, 2025

Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Nasdaq

Feb 26, 2025

Could This FDA Fast Track for Pyxis Oncology's Novel Cancer Drug Accelerate Treatment Options? - StockTitan

Feb 26, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Feb 26, 2025

Feb 25, 2025

Pyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% – Here’s What Happened - Defense World

Feb 25, 2025

Feb 24, 2025

Pyxis Oncology stock hits 52-week low at $1.23 amid downturn By Investing.com - Investing.com South Africa

Feb 24, 2025

Pyxis Oncology stock hits 52-week low at $1.23 amid downturn - Investing.com Canada

Feb 24, 2025

Feb 23, 2025

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? - Yahoo Finance

Feb 23, 2025

Feb 18, 2025